Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 February 2023Website:
http://mineralystx.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:03:15 GMTDividend
Analysts recommendations
Institutional Ownership
MLYS Latest News
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ: MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
What type of business is Mineralys Therapeutics?
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
What sector is Mineralys Therapeutics in?
Mineralys Therapeutics is in the Healthcare sector
What industry is Mineralys Therapeutics in?
Mineralys Therapeutics is in the Biotechnology industry
What country is Mineralys Therapeutics from?
Mineralys Therapeutics is headquartered in United States
When did Mineralys Therapeutics go public?
Mineralys Therapeutics initial public offering (IPO) was on 10 February 2023
What is Mineralys Therapeutics website?
https://mineralystx.com
Is Mineralys Therapeutics in the S&P 500?
No, Mineralys Therapeutics is not included in the S&P 500 index
Is Mineralys Therapeutics in the NASDAQ 100?
No, Mineralys Therapeutics is not included in the NASDAQ 100 index
Is Mineralys Therapeutics in the Dow Jones?
No, Mineralys Therapeutics is not included in the Dow Jones index
When was Mineralys Therapeutics the previous earnings report?
No data
When does Mineralys Therapeutics earnings report?
The next expected earnings date for Mineralys Therapeutics is 07 November 2024